Déclion Pharmaceuticals to Present at the BIO Investor Forum 2012 on October 9th

Oct 3 2012

Boxford, MA, October 3, 2012/PRNewswire/ -- Déclion Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today that Thomas P. Mathers, Chairman and Chief Executive Officer, will present a corporate update at the BIO Investor Forum 2012 in San Francisco, CA.  Mr. Mathers’ presentation is scheduled for Tuesday, October 9, 2012 at 2:00 p.m. in the Marina Room at the Palace Hotel. Mr. Mathers will also announce a new project financing capitalizing the development of two new disease modifying ModuloDEEP declensional peptides for treating Parkinson’s disease and tauopathies such as progressive supranuclear palsy (PSP), mild cognitive impairment (MCI) and Alzheimer’s disease (AD).

The Company will also be speaking with potential partners during both the BIO Investor Forum during one on one meetings.

About DEEPTM and Declensional Peptides

DEEP Technology is the Directed Expansion of Epitope Permutations through the manufacture of Amino Acid Copolymers with Antigenic Specificity, i.e., Declensional Peptides. These complex mixtures of 40-80 amino acid-long peptides are manufactured in a single solid phase peptide synthesis, incorporating more than one amino acid at a given position.

About Déclion Pharmaceuticals, Inc.

Déclion is a privately held biotechnology company founded in 2010 and focused on the development of declensional peptides for use as:

  1. Immunotherapeutic agents for treating neurodegenerative and autoimmune diseases
  2. Prophylactic and therapeutic vaccines for the treatment of infectious diseases and cancer

Ligands for antibody discovery

Key Déclion experience includes:

Eight years experience in GMP amino acid copolymer synthesis and batch-to-batch reproducibility

Eight orthogonal analytical methods for batch release

In vitro bioassays for batch release

Proprietary pharmacokinetic assay methods

 For more information, please visit www.declionpharma.com

Back to List